Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Endometrial Cancer 2Thrombosis 1Thrombophilia 1Solid Tumors 1Small Cell Lung Carcinoma 1Resectable Esophageal Squamous Cell Carcinoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Metastatic Solid Tumors 1Melanoma 1

Interventions

pembrolizumab 2lenvatinib 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Endometrial Cancer × Injections × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡